



Company name: KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President
(Securities Code: 4569, TSE 1st Sec.)

Release of **DESALEX[®] Tablets 5mg** for treatment of allergic diseases

TOKYO, JAPAN (November 18, 2016) - Kyorin Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc., announced the release of DESALEX[®] Tablets 5mg, a treatment for allergic diseases, under an exclusive distribution agreement.

DESALEX[®] Tablets is the second-generation antihistamine with new active ingredient. It is indicated for allergic rhinitis, urticaria, and pruritus associated with skin diseases (eczema, dermatitis, skin pruritus). MSD K.K. (Head office: Chiyoda-ku, Tokyo; President: Jannie Oosthuizen) received manufacturing and marketing approval in September 2016, and today the product was placed on the NHI price listing and released by Kyorin.

DESALEX[®] Tablets has the following characteristics:

- ① Has a high affinity for histamine H1 receptors
- ② Half life is long and a single daily dose suppresses symptoms for a long time
- ③ Fit patients' lifestyles because it is non-drowsy and unaffected by food

With the launch of the drug, Kyorin aims to further contribute to allergic diseases by continuously providing the latest information in our priority field of respiratory and otolaryngology. In the dermatological field, we have signed a contract regarding the co-promotion with Kaken Pharmaceutical Co., Ltd. (Head office: Bunkyo-ku, Tokyo, President and Representative Director: Tetsuo Onuma). Harnessing the strengths of both companies in developing promotional activities, we seek to maximize distribution of the product.

We expect sales of the drug in the initial year to reach nearly 1.9 billion yen. The sales of the drug is factored in consolidated forecast for the fiscal year ending March 31 2017.

■About 「DESALEX® Tablets」

Brand name	: DESALEX® Tablets
Active ingredient	: Desloratadine
Indication	: Allergic rhinitis, urticaria, and pruritus associated with skin diseases (eczema, dermatitis, skin pruritus)
Dosage and administration	: Normally for children aged 12 or older and adults, orally administer 5mg of desloratadine once daily.
NHI price	: ¥ 69.40
Packaging	: 100 tablets (PTP10 × 10) 、 140 tablets (PTP14 × 10) 500 tablets (PTP10 × 50) 、 700 tablets (PTP14 × 50)
Date of Drug Price Listing	: November 18, 2016
Date of Launch in Japan	: November 18, 2016

〈New product photo〉

